Modelling the Costs and Outcomes Associated With Sequence of Treatment With and Without Tofacitinib for the Treatment of Moderate to Severe Rheumatoid Arthritis in the Us
Value in Health - United Kingdom
doi 10.1016/j.jval.2015.03.932
Full Text
Open PDFAbstract
Available in full text
Date
May 1, 2015
Authors
Publisher
Elsevier BV